We work with a group of leading kidney health professionals and researchers, kidney consumers and people of influence to help steer our research agenda
Our national Research Advisory Group comprises some of Australia’s leading kidney health professionals and researchers, kidney consumers and people of influence. The Group provides ongoing input and support for our Research Strategy and Agenda and mission to ‘Improve the lives of all people affected by kidney disease through the support of research.’
Professor Steven James Chadban; BMed (hons), PhD, FRACP
Prof Chadban works as a clinician scientist at Royal Prince Alfred Hospital (RPAH), where he is Area Director of Renal Medicine, and as Leader of the Kidney Node, Charles Perkins Centre, University of Sydney.
He is the immediate past-President of TSANZ and current Councillor of The Transplantation Society. Professor Chadban also serves as Chair of the Transplant Liaison Advisory Group to The Australian Organ and Tissue Authority, Chair of the CKD group of the AIHW National Vascular Diseases Monitoring Group, and as a member of the ANZDATA Executive. He is Co-Chair of the KDIGO Guideline Group on Kidney Transplant Candidacy and a member of the NHMRC Ethical Guidelines for deceased and living donor transplantation groups.
Professor Chadban received the University Medal for Medicine in Newcastle, trained in Newcastle then moved to Monash to complete FRACP training in Nephrology and a PhD (1995-7) in kidney immunopathology, then a post-doc at Cambridge as a Jacquot scholar, prior to returning to Monash to run the kidney and pancreas transplant program and establish research teams in basic immunology, clinical transplantation and epidemiology of kidney disease. Prof Chadban moved to RPAH and University of Sydney in 2003.
Chadban has published over 200 papers, has over 11,000 citations and H-Index 54. His research themes include:
Chadban's goals are to better understand the causes of kidney and kidney transplant failure; to increase opportunities for patients to participate in clinical trials; to design and conduct clinical trials which bring lab discoveries to the clinic, address areas important to patients and clinicians, with longer follow-up at lower cost through use of clinical databases and Registries; to increase health care worker understanding and involvement in research; all in a bid to improve outcomes for patients in Australia and worldwide.
Peter Jon Hartshorne, Bsc Civ. Eng and MBA
Mr. Hartshorne was appointed to KHA Board in April 2008. He has a particular interest in research.
After serving a 6-year cadetship with McKinsey and Co. he went on to work for many top 100 international companies in the areas of Strategy and Technology enablement. He is now the Managing Director, Partner and Founder of The Infinity Group [established 1994] of companies, a private professional services firm in Australia, India and UK.
In addition, Mr. Hartshorne is Chairman of Scholaris International Ltd., an international education-based Software Company and Redgum Corporate Pty.Ltd. He is a member of the Remuneration and Succession Planning Committees and was appointed Chair of the KHA Finance Committee March 2016.
A/Prof Jesudason (MBBS, PhD, FRACP; née Prasad) is a Staff Specialist Nephrologist and Chair of the Clinical Research Group at the Royal Adelaide Hospital’s Central Northern Adelaide Renal and Transplant Service (CNARTS), the National Clinical Director of Kidney Health Australia and Associate Professor, University of Adelaide.
A/Prof Jesudason is an expert in CKD and pregnancy in patients with CKD. She has built substantial research capacity and grown the research workforce within CNARTS. In 2015, she established the CNARTS Clinical Research Group, conducting patient-centred studies to immediately influence clinical care through evidence-based practice changes, with a focus on the transition to dialysis; psychological resilience and coping; patient-reported outcome measures and symptom burden; community partnerships to inform kidney care for Indigenous patients. She is recognised as an expert on Parenthood in kidney patients, has been an invited speaker on Pregnancy and Renal Disease >30 times since 2012. She has published widely on this topic and her work is highlighted in Guidelines and clinical practice reviews. She established the only Obstetric Nephrology Service in SA in 2012, and her research has influenced models of care for women with CKD. She uses a broad array of methodologies (population data linkage, registry, cohort studies, qualitative, systematic reviews, basic science) to investigate parenthood outcomes for women and men with kidney disease. She is a senior researcher with the “Better evidence and Translation in Chronic Kidney Disease” (BEAT-CKD) Program. She is a lead contributor to the “Consumer Engagement in Research” stream which has spearheaded consumer engagement in research and scientific meetings across Australia and is involved in research projects with the ANZDATA registry pillar of BEATCKD. A/Prof Jesudason has extensive collaborations and investigator roles across diverse and multi-disciplinary projects with the BEATCKD program, ANZDATA Registry, The George Institute (including their Consumer and Community Engagement Working Group), SAHMRI Wardliparingga Aboriginal Research Unit, KHA-CARI Renal Guidelines Group, University of SA (Exercise Physiology, Pharmacology, Nursing), University of Adelaide )Pharmacology, Nursing, Aboriginal Health, Psychology), Robinson Institute Pregnancy and Birth group, AMOSS Obstetric Surveillance System, Standardised Outcomes in Nephrology (SONG) global initiative.
A/Prof Jesudason is the National Clinical Director of Kidney Health Australia (KHA), the peak body for people affected by kidney disease, and is highly experienced in consumer and community consultation. She leads the clinical directorate in RACGP-accredited education and resources about CKD care that reach > 46,000 primary health professionals. She co-leads and assisted in securing Federal funding (2018-2020) for 3 programs determining the future of kidney disease policy, strategy and care in Australia particularly for vulnerable patient cohorts: the national Community Consultations for the KHA-CARI Guidelines for Indigenous Patients with CKD, the KHA Youth Program and the Commonwealth National Strategic Action Plan for Kidney Disease (accepted by the DOH in October 2019). She is a national spokesperson and regularly discusses kidney disease in the media.
Professor A Richard Kitching is a Nephrologist at Monash Health and physician-scientist in the Department of Medicine at Monash University.
He is the Director of the Monash University Centre for Inflammatory Diseases and head of the Monash Health Vasculitis Clinic. His clinical practice in in Nephrology and in Paediatric Nephrology helps informs important questions in the causes of immune kidney disease and how they can be better treated.
His research is funded by the NMHRC. His research group working toward more targeted therapies for kidney diseases, in part by understanding the involvement of white blood cells in important causes of kidney disease, so that more targeted and effective treatments can be developed and used. It is regularly published in the most prestigious journals in kidney research, and also published in general journals including Nature, Nature Medicine, The New England Journal of Medicine, Proceedings of the National Academy of Sciences USA and the Journal of Clinical Investigation.
Prof Kitching is a member of the Editorial Boards of the Journal of the American Society of Nephrology (JASN), Kidney International, and the Clinical Journal of the American Society of Nephrology (CJASN). In 2007, he was awarded the Australian and New Zealand Society of Nephrology (ANZSN) TJ Neale Award for Outstanding Contribution to Nephrological Science. He was Chair of the ANZSN Scientific Program and Education Committee from 2007-2011, current Deputy Chair of the ANZSN Scientific Advisory Committee. He has served on NHMRC GRP Panels as a member, Deputy Chair and Chair.
Peter is now semi-retired having until recently completed 45 years in corporate life. He headed Leighton (now CIMIC) construction group based in Brisbane for 10 years of his 17 years with the group and was a Director of Leighton Contractors for 9 years. He returned to Victoria in 1996 to head up the development for the construction of the Melbourne City Link before branching out on his own in 1998 to for the McMullan – Williams Management Group that he headed up until selling in June this year. Peter led teams to develop, restructure and managed on behalf of GE, ABN Amro, ANZ and many high-profile companies, assets and corporate structures all over the World.
Peter, is also a transplant patient, blessed to receive a transplant on the 13 Sept. 13 after having spent 4 years as a Dialysis Patient. He first learnt of having kidney disease in 1998, in the form of IgA Nephrology with the decrease in kidney function having been traced back to a bout of “Ross River Fever” contracted in 1986 whilst building the Channel Island Power Station in Darwin.
On commencing Dialysis Peter with the desire to develop a level of health that would enable him to firstly receive a transplant kidney and secondly through achieving a higher level of health so gaining a level of self-respect through greater control of his outcomes. Fortunately, Peter had had a history in sport and setting a regime around a defined exercise program suited his rather determined nature. So, his initial program involved walking 12-15 km at least 4 times a week. Within six months he was alternating the walking with riding a bike 35-60km on the alternate days.
Nephrologist Professor Ian Fraser, who incidentally had been the person to diagnose his fate in 1998, noted that the personal effort was having a huge impact on his vitals and suggested Peter seek ways to advertise or promote his program to other patients and so the idea of “Pete’s Big Red Challenge” was born.
“Pete’s Big Red Challenge” saw Pete and a team of Friends walking out of Canberra on the 18th May 13. After 8 days walking and riding a bike arriving at the Royal Melbourne on Sunday 2nd June 13. Along the way preparing a video (for patients) to demonstrate that End Stage Kidney Decease need not be a ‘life sentence’ and raise critical funds to assist Royal Melbourne Hospital to engage staff to assist and encourage other sufferers to a better outcome.
Peter is pleased to offer his services to Kidney Health Australia to hopefully offer back something in gratitude for what the various teams in Kidney Health have provide him through his journey as a patient.
If you are a person affected by kidney disease and would like to help shape the future of kidney research, you can get involved in any aspect researchGet involved in research